@article{c42574e7ce2347cfb8ef9fb41f51a0dc,
title = "Normative brain volumetry derived from different reference populations: impact on single-subject diagnostic assessment in dementia",
abstract = "Brain imaging data are increasingly made publicly accessible, and volumetric imaging measures derived from population-based cohorts may serve as normative data for individual patient diagnostic assessment. Yet, these normative cohorts are usually not a perfect reflection of a patient's base population, nor are imaging parameters such as field strength or scanner type similar. In this proof of principle study, we assessed differences between reference curves of subcortical structure volumes of normal controls derived from two population-based studies and a case-control study. We assessed the impact of any differences on individual assessment of brain structure volumes. Percentile curves were fitted on the three healthy cohorts. Next, percentile values for these subcortical structures for individual patients from these three cohorts, 91 mild cognitive impairment and 95 Alzheimer's disease cases and patients from the Alzheimer Center, were calculated, based on the distributions of each of the three cohorts. Overall, we found that the subcortical volume normative data from these cohorts are highly interchangeable, suggesting more flexibility in clinical implementation.",
keywords = "Imaging, MRI, Normative data, Subcortical brain volume",
author = "{Alzheimer's Disease Neuroimaging Initiative} and Vinke, {Elisabeth J.} and Wyke Huizinga and Martin Bergtholdt and Adams, {Hieab H.} and Steketee, {Rebecca M.E.} and Papma, {Janne M.} and {de Jong}, {Frank J.} and Niessen, {Wiro J.} and Ikram, {M. Arfan} and Fabian Wenzel and Vernooij, {Meike W.}",
note = "Funding Information: This project has received funding from the European Union's Seventh Framework Programme for Research, Technological Development, and Demonstration under grant agreement no. 601055 (VPH-DARE@IT). This project has received funding from the European Union's Horizon 2020 Research and Innovation Programme under grant agreement No. 666992. This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme (project: ORACLE, grant agreement No: 678543). The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam; Netherlands Organization for the Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE); the Ministry of Education, Culture and Science; the Ministry for Health, Welfare and Sports; the European Commission (DG XII); and the Municipality of Rotterdam. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc; Cogstate; Eisai Inc; Elan Pharmaceuticals, Inc; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc; Fujirebio; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co, Inc; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. This research has been conducted using the UK Biobank Resource under Application Number 23509. Funding Information: This project has received funding from the European Union{\textquoteright}s Seventh Framework Programme for Research, Technological Development, and Demonstration under grant agreement no. 601055 (VPH-DARE@IT). This project has received funding from the European Union{\textquoteright}s Horizon 2020 Research and Innovation Programme under grant agreement No. 666992 . This project has received funding from the European Research Council (ERC) under the European Union{\textquoteright}s Horizon 2020 Research and Innovation Programme (project: ORACLE, grant agreement No: 678543 ). Funding Information: The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University , Rotterdam; Netherlands Organization for the Health Research and Development (ZonMw) ; the Research Institute for Diseases in the Elderly (RIDE) ; the Ministry of Education, Culture and Science ; the Ministry for Health, Welfare and Sports ; the European Commission (DG XII) ; and the Municipality of Rotterdam . Funding Information: Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) ( National Institutes of Health Grant U01 AG024904 ) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012 ). ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc; Cogstate; Eisai Inc; Elan Pharmaceuticals, Inc; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc; Fujirebio; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co, Inc; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Publisher Copyright: {\textcopyright} 2019 The Authors",
year = "2019",
month = dec,
doi = "10.1016/j.neurobiolaging.2019.07.008",
language = "English",
volume = "84",
pages = "9--16",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
}